Results 251 to 260 of about 264,642 (338)

EGFR Targeted Liposomal PROTAC Assisted With Epigenetic Regulation as an Efficient Strategy for Osimertinib‐Resistant Lung Cancer Therapy

Advanced Science, EarlyView.
In this study, an EGFR lipoSM PROTACs (GM‐protac), which can achieve efficient EGFR degradation and HDACi delivery, is developed. It is found that GM‐protac can both block EGFR‐dependent pathways and bypass the HDAC signaling pathway. Meanwhile, both display obvious tumor inhibition with negligible toxicity in EGFR‐TKI‐resistant lung cancer animal ...
Dongyuan Wang, Yajing Liu, Ying Chen, Chuan Dai, Wenzhu Hu, Jinyan Han, Zigang Li, Feng Yin, Yu Zhang, Chen Shi   +9 more
wiley   +1 more source

Immunotherapy against colorectal cancer via delivery of anti-PD-L1 nanobody mRNA. [PDF]

eGastroenterology
Chu WM, Ma L, Hew B, Sugawara A, Wengrill R, Guarary A, Irei JS, Chan O, Wang J, Muramtsu H, Moon W, Sharifai N, Boisvert W, Deng Y, Jia W, Pardi N, Anastasiadis P, Moisyadi S.   +17 more
europepmc   +1 more source

Harnessing the Power of the Immune System Via Blockade of PD-1 and PD-L1: A Promising New Anticancer Strategy [PDF]

, 2014
Kim A. Reiss, Patrick M. Forde, Julie R. Brahmer   +2 more
openalex   +1 more source

Scalable Lignin Monomer Production Via Machine Learning‐Guided Reductive Catalytic Fractionation of Lignocellulose

Advanced Science, EarlyView.
This study pioneers an integrated machine learning framework combining large‐scale data modeling, experimental validation, and impact analysis to optimize reductive catalytic fractionation for scalable, sustainable lignin monomer production. Abstract Efficient valorization of lignocellulosic biomass into high‐value lignin monomers is a cornerstone of ...
Meysam Madadi, Ehsan Kargaran, Seyed Sajad Hashemi, Chihe Sun, Joeri F.M. Denayer, Keikhosro Karimi, Fubao Sun, Vijai Kumar Gupta   +7 more
wiley   +1 more source

Targeting Exosomal PD-L1 as a New Frontier in Cancer Immunotherapy. [PDF]

Curr Issues Mol Biol
Dragu LD, Chivu-Economescu M, Pitica IM, Matei L, Bleotu C, Diaconu CC, Necula LG.   +6 more
europepmc   +1 more source

Immune Suppression in Premalignant Respiratory Papillomas: Enriched Functional CD4+Foxp3+ Regulatory T Cells and PD-1/PD-L1/L2 Expression

, 2012
Lynda Hatam, James A. DeVoti, David Rosenthal, Fung Lam, Allan L. Abramson, Bettie M. Steinberg, Vincent R. Bonagura   +6 more
openalex   +1 more source

CDK4/6 Inhibitor Priming Enhances PD‐1 Blockade via Sellhi Neutrophil‐Induced Stat5a+ Progenitor Exhausted CD8+ T Cell

Advanced Science, EarlyView.
Activated tumor‐intrinsic cyclin D1‐CDK4/6 signaling attenuates lymphocyte infiltration, and consequently, and immunotherapy resistance in HNSCC. It is discovered that brief CDK4/6i priming before anti‐PD‐1 results in enhanced durability of ICB response durability through Stat5a+ progenitor exhausted CD8+ T cells induced by IL15‐secreted Sell(hi ...
Yu Zhang, Bao Sun, Rong Zhou, Zizhen Gong, Yong Han, Wenjie Tao, Chaoji Shi, Wuchang Zhang, Laikui Liu, Zhiyuan Zhang, Jiang Li, Qi Zhu, Weiwen Zhu, Ziyue Gu   +13 more
wiley   +1 more source

Predicting ovarian cancer prognosis and immunotherapy response through siglec15 and PD-L1 expression analysis. [PDF]

Transl Oncol
Zhao A, Hu S, Qiu Y, Zhang P, Xu T.
europepmc   +1 more source

Targeting of the CD161 Inhibitory Receptor Enhances Bone‐Marrow‐Resident Memory CD8+ T‐Cell‐Mediated Immunity against Multiple Myeloma

Advanced Science, EarlyView.
CD161 is identified as a novel inhibitory receptor on bone marrow (BM)‐resident CD8⁺ T cells in multiple myeloma (MM). Through interaction with its ligand CLEC2D, CD161 impairs T‐cell function and promotes immune suppression. Blockade of CD161 restores tissue residency and cytotoxicity of CD8⁺ T cells and enhances chimeric antigen receptor T‐cell (CAR ...
Liwen Wang, Linzhi Xie, Yi Zhou, Shiming Tan, Yan Yu, Qin Zhang, Xuefeng Chen, Yuhan Yan, Ruiheng Luo, Han Xiao, Qian Cheng, Jian Zhang, Ying Li, Erhua Wang, Tiebin Jiang, Jing Liu, Xin Li   +16 more
wiley   +1 more source

Enhancing anti-tumor immunity by targeting BATF and the STAT1/PD-L1 pathway in cervical carcinoma. [PDF]

Cell Mol Life Sci
Peng X, Zhu Y, Han Y, Cai C.
europepmc   +1 more source